Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7291-7297

  Eshleman, Jeffrey S ^a   Carlson, Brett L ^a   Mladek, Ann C ^a   Kastner, Brian D ^a   Shide, Kathleen L ^a   Sarkaria, Jann N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; RAPAMYCIN; ROSCOVITINE;

ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; NUDE MOUSE; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; CELL DIVISION; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; SIROLIMUS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037115523     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Suit, H. D., Zietman, A., Tomkinson, K., Ramsay, J., Gerweck, L., and Sedlacek. R. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: A progress report. Int. J. Radiat. Oncol. Biol. Phys., 18: 365-373, 1990.
2. Taghian, A., DuBois, W., Budach, W., Baumann, M., Freeman, J., and Suit, H. In vivo radiation sensitivity of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 32: 99-104, 1995.
3. Labrousse, F., Daumas-Duport, C., Batorski, L., and Hoshino, T. Histological grading and bromodeoxyuridine labeling index of astrocytomas. Comparative study in a series of 60 cases. J. Neurosurg., 75: 202-205, 1991.
4. Onda, K., Davis, R. L., Shibuya, M., Wilson, C. B., and Hoshino, T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer (Phila.), 74: 1921-1926, 1994.
5. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys., 29: 427-431, 1994.
6. Maher, E. A., Fumari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., and DePinho, R. A. Malignant glioma: Genetics and biology of a grave matter. Genes Dev., 15: 1311-1333, 2001.
7. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Ottemess, D. M., Kamitz, L. M., and Abraham, R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 60: 3504-3513, 2000.
8. Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., and Fuller, G. N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet., 25: 55-57, 2000.
9. Frederick, L., Wang, X. Y., Eley, G., and James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res., 60: 1383-1387, 2000.
10. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A. C., and Van Meir, E. G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF. PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol., 9: 469-479, 1999.
11. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., and Stokoe. D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol., 8: 1195-1198, 1998.
12. Gingras, A. C., Raught, B., and Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev., 15: 807-826, 2001.
13. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273: 14424-14429, 1998.
14. Luo, Y., Marx, S., Kiyokawa, H., Koff, A., Massague, J., and Marks, A. Rapamycin resistance tied to defective regulation of p27Kip1. Mol. Cell. Biol., 16: 6744-6751, 1996.
15. Grewe, M., Gansauge, F., Schmid, R. M., Adler. G., and Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res., 59: 3581-3587, 1999.
16. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. RAFTI: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 78: 35-43, 1994.
17. 1-arresting rapamycin-receptor complex. Nature (Lond.), 369: 756-758, 1994.
18. Kahan, B. D., and Camardo, J. S. Rapamycin: Clinical results and future opportunities. Transplantation, 72: 1181-1193, 2001.
19. Withers, H. R., and Peters, L. J. Transmutability of dose and time. Commentary on the first report of RTOG 90003 (K. K. Fu et al.). Int. J. Radiat. Oncol. Biol. Phys., 48: 1-2, 2000.
20. Fowler, J. F., and Harari. P. M. Confirmation of improved local-regional control with altered fractionation in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 48: 3-6, 2000.
21. Jones, B., and Dale, R. G. Inclusion of molecular biotherapies with radical radiotherapy: Modeling of combined modality treatment schedules. Int. J. Radiat. Oncol. Biol. Phys., 45: 1025-1034, 1999.
22. Little, J. B., Hahn, G. M., Frindel, E., and Tubiana, M. Repair of potentially lethal radiation damage in vitro and in vivo. Radiology, 106: 689-694, 1973.
23. pot) of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Res., 53: 4413-4417, 1993.
24. 1 restriction point into S-phase: Implications for fluoropyrimidine radiosensitization. Cancer Res., 60: 92-100, 2000.
25. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., and Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 59: 886-894, 1999.
26. Sham, E., and Durand, R. E. Cell kinetics and repopulation mechanisms during multifraction irradiation of spheroids. Radiother. Oncol., 46: 201-207, 1998.
27. Duchesne, G. M., and Peacock, J. H. Radiation cell survival and growth delay studies in multicellular spheroids of small-cell lung carcinoma. Int. J. Radiat. Biol. Phys. Chem. Med., 51: 365-375, 1987.
28. Sutherland, R. M. Cell and environment interactions in tumor microregions: The multicell spheroid model. Science (Wash. DC), 240: 177-184, 1988.
29. Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., and Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 243: 527-536, 1997.
30. Fowler, J. F., and Lindstrom, M. J. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 23: 457-467, 1992.
31. Sarkaria, J., Fowler, J., Lindstrom, M., Jordan, V., and Mulcahy, R. The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time. Int. J. Radiat. Oncol. Biol. Phys., 31: 833-840, 1995.
32. Harari, P. M., and Huang, S. M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin. Radiat. Oncol. 11: 281-289, 2001.
33. 2-M delay. Clin. Cancer Res., 3: 1149-1156, 1997.
34. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and Schreiber. S. L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA, 96: 14866-14870, 1999.
35. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., and Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med., 8: 128-135, 2002.
36. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14: 391-396, 2000.
37. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
38. Maity, A., Pore, N., Lee, J., Solomon, D., and O'Rourke, D. M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res., 60: 5879-5886, 2000.
39. Hess, C., Vuong, V., Hegyi, I., Riesterer, O., Wood, J., Fabbro, D., Glanzmann, C., Bodis, S., and Pruschy, M. Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer, 85: 2010-2016, 2001.
40. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and Weichselbaum, R. R. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res., 59: 3374-3378, 1999.
41. Geng, L., Donnelly, E., McMahon, G., Lin, P. C., Sierra-Rivera, E., Oshinka, H., and Hallahan, D. E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res., 61: 2413-2419, 2001.
42. Ning, S., Laird, D., Cherrington, J. M., and Knox, S. J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res., 157: 45-51, 2002.